Latest News

Pulmonary Valve Replacement-VENUS-MEDTECH agreement

November 7th, 2022

RSK Medical Inc. is pleased to announce a distribution agreement with VENUS-MEDTECH, a leader in transcatheter structural heart valve therapies in Asia and Europe.  RSK Medical is distributing the VENUS-P Valve system which is the first self-expanding nitinol stent designed specifically for pulmonary valve replacement.
The purpose of the VENUS-P is to replace the native or repaired  pulmonary heart valve with an artificial (biological) valve using a minimally invasive approach to treat RVOT dysfunction to restore proper pulmonary valve function.
To date, VENUS-P Valve implants have been completed at St. Paul’s Hospital, Toronto General Hospital and the Montreal Heart Institute under the special access process via Health Canada.

RSK Medical Inc. is pleased to announce a partnership with TOZUDA Inc. to distribute their HEAD IMPACT SENSOR across Canada.

May 26th, 2022

“TOZUDA came to my attention on LinkedIn as I have suffered a few concussions myself while playing football, hockey and downhill skiing in my past, said President, Scott Kadwell of RSK Medical Inc.. “I was also touched by the movie called “Concussion” depicting the findings of pathologist Dr. Bennett Omahu who brought the issue of brain damage to the forefront amongst NFL football players and the public domain. He discovered “Chronic Traumatic Encephalopathy” (CTE) in Pittsburgh Steeler players who had experienced repeated head blows which had terrible effects on their medical conditions and lifespan.

“It is easy for parents or coaches to assume players will not incur head injuries and some associations are afraid to acknowledge even the best protocols will not pick up all the head injuries due to the nature of the support and how hits impact people differently”. “Intentional or accidental hits are going to happen”. “It is important to have the “peace of mind” that the high impact hits will get checked out”. It is scientifically documented that 50% of head injuries go under diagnosed or undetected. In addition, 90% of diagnosed head injuries do not involve a loss of consciousness. Each additional hit is accumulative to causing further damage to the injured brain.

The TOZUDA Head Impact Sensor can be easily attached to hockey, snowboarding, snow-skiing, football, cycling and construction helmets to name a few. Please check out the www.tozuda.com website for further information or contact RSK Medical Inc. at generalinquiry@rskmedical.com

Please take note we also represent electroCore which manufactures a non-invasive Vagus Nerve Stimulator (nVNS) called the Sapphire for treatment of migraine and cluster headaches.

RSK Medical Inc. is pleased to announce a nationwide distribution agreement with Texray AB

April 28th, 2022

RSK Medical Inc. is pleased to announce a nationwide distribution agreement with Texray AB located in Kungsbacka, Sweden effective immediately.

Texray has invented the only radiation protection textile in the world.  Their unique material and product design can reduce scatter radiation towards the head and neck by up to 97% to enhance the safety of healthcare professionals.

The Texray product line can be used in interventional electrophysiology, cardiology, radiology and endovascular surgery procedures where RSK Medical already offers other specialty products.

We look forward to introducing the Texray radiation protection products across Canada.

Read more at the Texray web site.

electroCore Sapphire receives Adolescent Approval for migranes in Canada

October 6th, 2021

It’s an absolute pleasure to share the news that gammaCore Sapphire now has the approval for adolescent migraine treatment in Canada. Specifically, our indication for use in Canada now reads;

gammaCore Sapphire (non-invasive vagus nerve stimulator) is indicated for:

  • Preventive treatment of cluster headache in adult patients.
  • Acute treatment of cluster headache in adult patients.

And now!

  • Preventive treatment of migraine headache in adolescent (age 12 and older) and adult patients.
  • Acute treatment of migraine headache in adolescent (age 12 and older) and adult patients.

New distribution agreement with ProCell Surgical Inc.

Spetember 25th, 2021

RSK Medical Inc. is pleased to announce a new nationwide distribution agreement with ProCell Surgical Inc. effective October 1st/2021. The ProCell device is a patient blood management system device used during surgical procedures requiring intraoperative autotransfusions. Their unique blood management system enhances a hospital’s surgical blood conservation efforts during surgery and provides added safety to the patient by utilizing their own blood vs. transfusions.

The ProCell has potential use in trauma, cardiac, vascular, transplant and orthopaedic surgical procedures. This product nicely complements RSK Medical current product portfolio serving these specialty surgical areas.

We look forward to introducing the unique and cost-effective ProCell technology across Canada.

First Patients in Canada Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

August 20th, 2021

ST. PAUL, Minn.–(BUSINESS WIRE)– Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Canada have been treated with its Diamondback 360®Coronary Orbital Atherectomy System (OAS).

The first patients in Canada were treated by Sanjog Kalra, MD, Interventional Cardiologist and Cardiac Critical Care Physician at the Peter Munk Cardiac Centre, Toronto General Hospital, part of the University Health Network.

Read more.

Migraine Canada’s comprehensive blog entry outlines the GammaCore Sapphire Device.

July 20th, 2021

“What is it? The gammaCore SapphireTM (nVNS)  is a hand-held device that the patient uses to stimulate the vagus nerve in the neck.  The vagus nerve is an important highway of communication between the body and the brain and plays an important role in regulating pain.”

Read more.

RSK MEDICAL Inc. delivers first Sapphire devices in Canada.

April 30, 2021

RSK Medical Inc. ships first electroCore gamma Sapphire non-invasive vagal nerve stimulation systems (nVNS) for primary headache prevention and treatment (cluster and migraine). Order/authorization forms signed by a Canadian medical licenced physician are required before shipment. Please see www.gammacoreCanada.com for further information.

RSK Medical Inc. signs agreement with Cardiovascular Systems, Inc.

April 30, 2021

RSK Medical Inc. and Cardiovascular Systems Inc.(CSI), manufacturers of the proven Diamondback 360 orbital rotational atherectomy systems for peripheral and coronary use have signed an agent representation agreement for sales, marketing and clinical support across Canada. The Diamondback 360 offers a low profile (6Fr compatible) system for the radial or femoral approach. The system has a unique mechanism of action (MOA) using a combination of centrifugal force and differential sanding to safely and simply reduce arterial calcium to enable successful stent delivery. The two platforms have been fully approved by Health Canada and we look forward to launching Diamondback 360 over the next few months. Please see www.csi360.com for further product details and clinical data.

electroCore, Inc. Announces Regulatory Approval in Canada

April 5, 2021

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in Canada for prevention and therapeutic treatment of migraine and cluster headache, as outlined in the registration application with Health Canada.

gammaCore Sapphire will be distributed in Canada by RSK Medical Inc., pursuant to an exclusive distribution agreement announced on January 26, 2021. The initial term of the agreement is three years, and the agreement contains customary terms and conditions, including minimum purchase commitments. “Patients and clinicians in Canada have been waiting years for this novel migraine and cluster headache therapy. RSK Medical Inc. is delighted to bring another breakthrough medical device technology to the Canadian marketplace. We look forward to working towards provincial healthcare funding for this patient group” said Scott Kadwell, President of RSK Medical Inc.

“Migraine Canada is pleased to learn that a new device to treat migraine and cluster headaches has been approved by Health Canada. Timely and equitable access to diverse and affordable treatment options and devices are essential for patients living with these painful and debilitating diseases” said Dr. Elizabeth Leroux, president of the Canadian Headache Society and the founder and chair of Migraine Canada.

New Distribution Agreement with Angiodroid, manufacturer of the CO2 Injector

March 24, 2021

RSK Medical Inc. has signed a long term agreement (Canada-wide) to represent Angiodroid Srl from Bologna, Italy.

Angiodroid manufacturers The CO2 Injector, the first system for Automated Carbon Dioxide Angiography (ACDA) dedicated to diagnostic and interventional procedures in peripheral and venous systems.

The Safety and Efficacy of Angiodroid’s CO2 injector has been validated in over 20 international clinical studies to date. This technology makes it possible to use CO2, a 100% biocompatible gas to obtain high quality radiological angiographic images while preserving the renal function of the patients. The ACDA system system avoids all contrast induced nephropathy risks and potential for allergic reactions.

Angiodroid has begun preparation for submitting for Health Canada regulatory approval. Find more on www.angiodroid.com.

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

January 26, 2021

ROCKAWAY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medical Inc. (“RSK Medical”) whereby RSK Medical will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Canada, supplying therapy to patients suffering with primary headache disorders.

“We are delighted to partner with RSK Medical as we look to expand the geographical coverage of our nVNS therapy amongst patients suffering with migraine and cluster headache,” said Iain Strickland, Vice President of European Operations. “RSK is an experienced medical device supplier and we warmly welcome Scott Kadwell and the RSK Medical team into our network of select distribution partners. We look forward to supporting RSK Medical in their market access activities and in our common goal of providing Canadian clinicians and patients with our proven therapeutic medical device, gammaCore Sapphire.”

“RSK Medical Inc. is excited to partner with electroCore to provide a personalized medicine approach to Canadian patients to address an unmet clinical need for primary headache disorders,” said Scott Kadwell, President of RSK Medical.

The gammaCore Sapphire system will be released upon receiving regulatory approval in Canada, anticipated in the next few months.

RSK MEDICAL SIGNS with CRYOTHERMIC SYSTEMS

November 17, 2020

“RSK Medical Inc. is pleased to announce a nationwide distribution agreement with Cryothermic Systems Inc.  The Cryothermic Cooling Elements and Wrap are used to provide fast and effective cooling method for initiation and continued cooling of patients following cardiac arrest, fever or heat stroke.  There are numerous applications in EMS transport, Cardiac Cath Labs, Emergency and ICU Departments.  The Cyro cooling system can also act as a bridge to targeted temperature management (TTM) and longer term cooling.”  Numerous testimonials have been documented by U.S. EMS and ICU staff that have experienced its ease of use and effectiveness in reducing patient’s core temperature 1.5-3.0 C degrees in 20-30 minutes.

Prytime Medical Health Canada approval for New ER-REBOA PLUS Catheter

November 17, 2020

Prytime Medical Devices, Inc. introduced its latest aortic occlusion catheter. The ER-REBOA PLUS catheter is designed for improved ease of use, now guide wire-compatible (up to .025 “) with improved depth markings for insertion without imaging.

“The original ER-REBOATM catheter was an important start in delivering a new technology to help clinicians stabilize and manage certain scenarios of bleeding and shock; a technology that, to date, has contributed to saving hundreds of lives,” said Col. (Dr.) Todd Rasmussen, Director of the Battlefield Shock and Resuscitation Research Program at the Uniformed Services University of the Health Sciences. “However, we recognized from the outset that the original design and device would evolve. Even iterative changes in the technology, such as with the ER-REBOATM PLUS, stand to make the devices easier to use, safer and more effective.“

Distribution agreement with NeoChord Inc.

September 08, 2020

RSK Medical Inc. is pleased to announce the signing of a distribution agreement with NeoChord Inc., a privately held medical technology company leading the advancement of mitral valve repair (MVR) in patients suffering from mitral regurgitation.  The NeoChord procedure is a beating heart, echo-guided treatment option for patients with MVR and is proven to resolve and restore normal mitral valve function.  The technology allows for a minimally invasive procedure for moderate to severe degenerative disease while the heart is beating and without the need for cardio-pulmonary bypass or aortic cross-clamping.

COVID-19 Statement

May 02, 2020

RSK Medical Inc. and its many suppliers would like to thank all the medical care providers and essential workers for their heroic efforts during the current COVID-10 pandemic.  The great commitment and continued support will not be forgotten.

Pain and Anxiety Post Sternotomy – A Personal Experience

April 01, 2020

What is it like to have the most important bone in your body split in half, exposing, arguably the most important organs in your body, the heart, and lungs?  In two words, frightening and painful! Having been in the Cardio Vascular marketplace for over 30 years, I had seen many of these procedures up close and personal as a part of my job selling and installing heart valves, oxygenators pumps, etc.

Read more about this item

PRYTIME MEDICAL™ Celebrates 500th Documented Life Saved

December 05, 2019

“500 lives saved during the relatively young life of this technology is a remarkable accomplishment and great example of how innovation in military medicine benefits the broader public.” says Dr. Todd E. Rasmussen.

Read more about this item

Prytime Medical™ Devices, Inc. Launches STAAR (Simulation Trainer for Arterial Access and REBOA) to Support Global Training

August 22, 2019

Prytime Medical Devices Inc., today announced the launch of the Prytime Medical STAAR (Simulation Trainer for Arterial Access and REBOA).

Read more about this item

RSK Medical Inc signs nationwide sales agent agreement with Prytime Medical-The REBOA Company effective June 1st/2019

May 1st, 2019

Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive technique to temporarily occlude large vessels in support of hemorrhage control.

PO Box 30040 RPO Boxgrove
90 Copper Creek Dr.
Markham, Ontario
L6B 0R5 Canada